Virtu Financial LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 15,214 shares of the medical device company's stock, valued at approximately $1,020,000.
Several other institutional investors have also recently added to or reduced their stakes in DXCM. Jennison Associates LLC lifted its position in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock worth $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock worth $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Two Sigma Advisers LP boosted its stake in DexCom by 182.7% in the third quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company's stock valued at $76,659,000 after acquiring an additional 739,000 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in DexCom by 189.1% in the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company's stock valued at $75,471,000 after acquiring an additional 435,401 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in shares of DexCom by 2,083.0% during the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company's stock worth $25,967,000 after purchasing an additional 369,587 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.
DexCom Price Performance
Shares of DexCom stock traded down $1.74 during trading on Friday, reaching $77.19. The company's stock had a trading volume of 2,956,879 shares, compared to its average volume of 3,884,590. The business has a 50 day moving average price of $73.76 and a 200-day moving average price of $84.65. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a market capitalization of $30.15 billion, a P/E ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.
Analysts Set New Price Targets
A number of analysts recently issued reports on the company. Sanford C. Bernstein upped their target price on DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Wells Fargo & Company increased their price objective on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a report on Wednesday. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. JPMorgan Chase & Co. upped their price target on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Finally, Leerink Partners lowered their price objective on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.00.
Read Our Latest Stock Report on DXCM
Insiders Place Their Bets
In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company's stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.30% of the company's stock.
About DexCom
(
Free Report)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
See Also
Before you consider DexCom, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.
While DexCom currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
